Condition: Relapsed or Refractory Peripheral T-cell Lymphoma · Sponsor: Great Novel Therapeutics Biotech & Medicals Corporation
This is a phase II, open-label, non-randomized, single-arm, multicenter study to evaluate the efficacy, safety, and PK of chidamide in patients with R/R PTCL.
This description comes directly from the study's public registry record.
Chia-Nan Chen, Ph.D. · 886-2-2785-1399 · alex.chen@gntbm.com.tw
Always discuss trial participation with your own doctor first.
| Chang Gung Memorial Hospital, Kaohsiung | Kaohsiung City, Taiwan | Recruiting |
| Kaohsiung Medical University Chung-Ho Memorial Hospital | Kaohsiung City, Taiwan | Recruiting |
| Far eastern memorial hospital | New Taipei City, Taiwan | Recruiting |
| Taichung Veterans General Hospital | Taichung, Taiwan | Recruiting |
| National Taiwan University Hospital | Taipei, Taiwan | Recruiting |
| Chang Gung Memorial Hospital, Linkou | Taoyuan, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05833724